Schizophrenia Research Trends

Schizophrenia Research Trends
Author: Konstance V. Almann
Publisher: Nova Publishers
Total Pages: 284
Release: 2007
Genre: Medical
ISBN: 9781600217463

Schizophrenia is a chronic, severe, and disabling psychosis, which is an impairment of thinking in which the interpretation of reality is abnormal. Psychosis is a symptom of a disordered brain. Approximately One percent of the population worldwide develops schizophrenia during their lifetime. Although schizophrenia affects men and women with equal frequency, the disorder often appears earlier in men, usually in the late teens or early twenties, than in women, who are generally affected in the twenties to early thirties. People with schizophrenia often suffer symptoms such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts, or plotting to harm them. The current evidence concerning the causes of schizophrenia are many. It is quite clear that multiple factors are involved. These include changes in the chemistry of the brain, changes in the structure of the brain, and genetic factors. Viral infections and head injuries may also play a role. New molecular tools and modern statistical analyses allow focusing in on particular genes that might make people more susceptible to schizophrenia by affecting, for example, brain development or neurotransmitter systems governing brain functioning. State-of-the-art imaging techniques are being used to study the living brain. They have recently revealed specific, subtle abnormalities in the structure and function of the brains of patients with schizophrenia. In other imaging studies, early biochemical changes that may precede the onset of disease symptoms have been noted, prompting examination of the neural circuits that are most likely to be involved in producing those symptoms. This book presents new and important research in the field.

Trends in Schizophrenia Research

Trends in Schizophrenia Research
Author: Mary V. Lang
Publisher: Nova Publishers
Total Pages: 236
Release: 2005
Genre: Psychology
ISBN: 9781594541544

Schizophrenia is a chronic, severe, and disabling psychosis, which is an impairment of thinking in which the interpretation of reality is abnormal. Psychosis is a symptom of a disordered brain. Approximately 1 percent of the population worldwide develops schizophrenia during their lifetime. Although schizophrenia affects men and women with equal frequency, the disorder often appears earlier in men, usually in the late teens or early twenties, than in women, who are generally affected in the twenties to early thirties. People with schizophrenia often suffer symptoms such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts, or plotting to harm them. The current evidence concerning the causes of schizophrenia is a mosaic. It is quite clear that multiple factors are involved. These include changes in the chemistry of the brain, changes in the structure of the brain, and genetic factors. Viral infections and head injuries may also play a role New molecular tools and modern statistical analyses are allowing focusing in on particular genes that might make people more susceptible to schizophrenia by affecting, for example, brain development or neurotransmitter systems governing brain functioning. State-of-the-art imaging techniques are being used to study the living brain. They have recently revealed specific, subtle abnormalities in the structure and function of the brains of patients with schizophrenia. In other imaging studies, early biochemical changes that may precede the onset of disease symptoms have been noted, prompting examination of the neural circuits that are most likely to be involved in producing those symptoms. This new book presents the newest in-depth research from around the world on schizophrenia.

Schizophrenia Treatment Outcomes

Schizophrenia Treatment Outcomes
Author: Amresh Shrivastava
Publisher: Springer Nature
Total Pages: 351
Release: 2020-02-05
Genre: Psychology
ISBN: 3030198472

This book analyzes schizophrenia management in the context of recent clinical therapeutic advances that have transformed the measurements and outcomes landscape. Unlike any other resource, this volume carefully develops the social and clinical guidelines that affect the life of the patient and defines its role in schizophrenia treatment outcomes. The text begins by determining the concepts, development, neuroscience, and guidelines for positive outcomes before analyzing the gaps in the literature. The text addresses medical concerns in relation to outcomes in schizophrenic patients, including substance use, impact from antipsychotic medications, and medical comorbidities. The text also covers external determinants that may inhibit positive outcomes, including cultural factors, stigma, and environmental issues. Written by experts in schizophrenia care, this book compiles sound research, current clinical trends, and modern measurement markers into a well-organized compendium that delivers this data into a practical guide for measuring treatment outcomes in patients suffering from the disease. Schizophrenia Treatment Outcomes is the ultimate guide for psychiatrists, psychologists, nurses, social workers, and all medical practitioners interested in improving outcomes for schizophrenia patients.

Schizophrenia Research

Schizophrenia Research
Author: Carol A. Tamminga
Publisher: Lippincott Williams & Wilkins
Total Pages: 402
Release: 1991
Genre: Medical
ISBN:

Outlines the most promising research in a number of disciplines investigating the biological basis of schizophrenia. Considering scientific findings and techniques in both neuroscience and psychosocial work, the sections cover biochemistry, neurobiology and physiology, behavior, the schizophrenia spectrum, and psychosocial and pharmacological treatments. Among the 35 specific topics are recent developments in genetic linkage studies, autoimmunity, stress, an argument for neurobiological homogeneity, a neuropsychiatric model of treatment, and neuroleptic noncompliance. Begins a new series. Annotation copyrighted by Book News, Inc., Portland, OR

Schizophrenia

Schizophrenia
Author: Steven M. Silverstein
Publisher: MIT Press
Total Pages: 403
Release: 2013-11-15
Genre: Medical
ISBN: 0262019620

Leading researchers address conceptual and technical issues in schizophrenia and suggest novel strategies for advancing research and treatment. Despite major advances in methodology and thousands of published studies every year, treatment outcomes in schizophrenia have not improved over the last fifty years. Moreover, we still lack strategies for prevention and we do not yet understand how the interaction of genetic, developmental, and environmental factors contribute to the disorder. In this book, leading researchers consider conceptual and technical obstacles to progress in understanding schizophrenia and suggest novel strategies for advancing research and treatment. The contributors address a wide range of critical issues: the construct of schizophrenia itself; etiology, risk, prediction, and prevention; different methods of modeling the disorder; and treatment development and delivery. They identify crucial gaps in our knowledge and offer creative but feasible suggestions. These strategies include viewing schizophrenia as a heterogeneous group of conditions; adopting specific new approaches to prediction and early intervention; developing better integration of data across genetics, imaging, perception, cognition, phenomenology, and other fields; and moving toward an evidence-based, personalized approach to treatment requiring rational clinical decision-making to reduce functional disability. Contributors Robert Bittner, Robert W. Buchanan, Kristin S. Cadenhead, William T. Carpenter, Jr., Aiden Corvin, Daniel Durstewitz, André A. Fenton, Camilo de la Fuente-Sandoval, Jay A. Gingrich, Joshua A. Gordon, Chloe Gott, Peter B. Jones, René S. Kahn, Richard Keefe, Wolfgang Kelsch, James L. Kennedy, Matcheri S. Keshavan, Angus W. MacDonald III, Anil K. Malhotra, John McGrath, Andreas Meyer-Lindenberg, Kevin J. Mitchell, Bita Moghaddam, Vera A. Morgan, Craig Morgan, Kim T. Mueser, Karoly Nikolich, Patricio O'Donnell, Michael O'Donovan, William A. Phillips, Wulf Rössler, Louis Sass, Akira Sawa, Jeremy K. Seamans, Steven M. Silverstein, William Spaulding, Sharmili Sritharan, Heike Tost, Peter Uhlhaas, Aristotle Voineskos, Michèle Wessa, Leanne M. Williams, Ashley Wilson, Til Wykes

Ending Discrimination Against People with Mental and Substance Use Disorders

Ending Discrimination Against People with Mental and Substance Use Disorders
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Total Pages: 171
Release: 2016-09-03
Genre: Social Science
ISBN: 0309439124

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.

Psychopharmacology: Current Trends

Psychopharmacology: Current Trends
Author: Daniel E. Casey
Publisher: Springer
Total Pages: 0
Release: 2011-12-27
Genre: Medical
ISBN: 9783642732829

The landmark description by Delay and Deniker in 1952 of chlorpromazine's effect in psychosis suddenly eclipsed all other progress in psychopharmacology over the previous centuries. Since this report 35 years ago, a vast amount of research has contributed to the major advances in treatment that have improved the lives of millions of patients who would otherwise be incapacitated by their psychiatric disorders. This research has also led to valuable new insights into the causes of mental illnesses and the mechanisms of action of therapeutic drugs. However, there is much more work to be done. Thus, it is of great value periodically to assess the present state of knowledge as a first step to charting future directions. This symposium held in Denmark in 1987 covered many critical issues in psychopharmacology. The etiology, pathogenetic mechanisms, clinical aspects, and future directions of research in schizophrenia, affective disorders, anxiety, and dementia are addressed. Several of the problems with current therapeutic agents, such as side effects and limited efficacy, are also reviewed. Preclinical strategies with existing and new animal and computer models are discussed to point the way for developing better psychopharmacologic treatments of all psychiatric disorders.